enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Triple-negative breast cancer - Wikipedia

   en.wikipedia.org/wiki/Triple-negative_breast_cancer

   Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tumor is negative on all three tests giving the name triple-negative). [1]

3. Endocrine therapy resistance in breast cancer - Wikipedia

   en.wikipedia.org/wiki/Endocrine_therapy...

   Luminal B (ER and/or PR positive; HER2 positive) HER2-enriched (ER/PR negative; HER2 positive) Basal like (triple negative). [6] Additionally, cancers can be ER-/PR+ or ER+/PR-, but these are unnamed and relatively rare. [7] The receptor status of a cancer is assessed for all breast cancers as it has important implications on prognosis of the ...

4. HER2 - Wikipedia

   en.wikipedia.org/wiki/HER2

   HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. But contrary to other members of the ERBB family, HER2 does not directly bind ligand. HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration are high, for instance in cancer. [8]

5. Basal-like carcinoma - Wikipedia

   en.wikipedia.org/wiki/Basal-like_carcinoma

   The basal-like carcinoma is a recently proposed subtype of breast cancer defined by its gene expression and protein expression profile. [1]Breast cancer can be divided into five molecular subtypes, including luminal subtype A, luminal subtype B, normal breast-like subtype, HER-2 overexpression subtype, and basal-like subtype. [2]

6. Invasive carcinoma of no special type - Wikipedia

   en.wikipedia.org/wiki/Invasive_carcinoma_of_no...

   The treatment of invasive carcinoma NST is often similar to management plans for other invasive breast carcinomas. The treatment options offered to an individual patient are determined by the form, stage and location of the cancer, and also by the age, history of prior disease and general health of the patient.

7. Breast cancer classification - Wikipedia

   en.wikipedia.org/wiki/Breast_cancer_classification

   Cells with none of these receptors are called basal-like or triple negative. HER2-low has some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive. [4] Trastuzumab deruxtecan is the first approved therapy by the US Food and Drug Administration (FDA) targeted to people with the HER2-low breast cancer subtype. [4]

8. Antibody–drug conjugate - Wikipedia

   en.wikipedia.org/wiki/Antibody–drug_conjugate

   Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, trade name: Kadcyla, marketed by Genentech and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment with trastuzumab and a taxane chemotherapy. [13] [14]

9. Fulvestrant - Wikipedia

   en.wikipedia.org/wiki/Fulvestrant

   Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. [2]